3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
15
Gynecologic
9
Thoracic
8
Genitourinary
8
Head & Neck
5
Dermatologic
3
NET
2
Endocrine
2
CNS
2
Breast
2
Sarcoma
1
Conditions
Neuroendocrine Tumors
117
Gastro-enteropancreatic neuroendocrine tumor
21
Neoplasms
20
Carcinoid Tumor
17
Colorectal Neoplasms
13
Carcinoma, Neuroendocrine
11
Neoplasm Metastasis
10
Carcinoma
10
Lung Neoplasms
9
Small Cell Lung Carcinoma
8
Prostatic Neoplasms
8
Carcinoma, Renal Cell
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Sarcoma
7
Pancreatic Neoplasms
7
Carcinoma, Hepatocellular
7
Adenoma, Islet Cell
7
Stomach Neoplasms
6
Serotonin Syndrome
6
Pheochromocytoma
6
Melanoma
6
Head and Neck Neoplasms
6
Digestive System Neoplasms
6
Cholangiocarcinoma
6
Thyroid Neoplasms
5
Paraganglioma
5
Ovarian Neoplasms
5
Gastroenteropancreatic Neuroendocrine Tumors
5
Colonic Neoplasms
5
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
NET
×
Clear all
NCT07377487
2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA
Recruiting
51 enrolled
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA